Hepatit B yrkesrisk för vårdpersonal: Vaccination rekommenderas som profylax

Lakartidningen

Volumn 93, Issue 10, 1996, Pages 884-888

  Strove, Johan ^a,e   Aronsson, B O ^b   Forsgren, Marianne ^c   Frenning, Bertil ^d   Von Sydow, Madeleine ^c   Weiland, Ola ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Riksförsäkringsverkets Sjukhus

^e DANDERYD HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B VACCINE;

ARTICLE; BLOODBORNE BACTERIUM; DISEASE TRANSMISSION; HEPATITIS B; HOSPITAL PERSONNEL; HUMAN; IMMUNOLOGY; RISK FACTOR; SWEDEN;

BLOOD-BORNE PATHOGENS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; PERSONNEL, HOSPITAL; RISK FACTORS; SWEDEN;

EID: 0030571805     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Recommendations of the Immunization Practices Advisory Committee (ACIP). Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR Morb Mortal Wkly Rep 1991; 40: 1-25.
2. Struve J, Aronsson B, Frenning B, Forsgren M, Weiland O. Prevalence of hepatitis B virus markers and exposure to occupational risks likely to be associated with acquisition of hepatitis B virus among health care workers in Stockholm. J Infect 1992; 24: 147-56.
3. Socialstyrelsens författningssamling. Socialstyrelsens allmänna råd om förebyggande åtgärder mot hepatit B. SOSFS 1991; 2: 1-10.
4. Struve J, Aronsson B, Frenning B, Granath F, von Sydow M, Weiland O. Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: A comparison of response rates and an analysis of factors influencing the antibody response. Scand J Infect Dis 1992; 24: 423-9.
5. Struve J, Aronsson B, Frenning B, Forsgren M, Weiland O. Response to a booster dose after a low anti-HBs response (10-99 IU/1) to three doses of intradermally or intramuscularly administrated recombinant hepatitis B vaccine. Infection 1995; 23: 42-5.
6. Struve J, Aronsson B, Forsgren M, Frenning B, Weiland O. Seroconversion after additional vaccine doses to non-responders to three doses of intradermally or intramuscularly administred recombinant heaptitis B vaccine. Scand J Infect Dis 1994; 26: 468-70.
7. Morris CA, Oliver PR, Reynolds F, Selkon JB. Intradermal hepatitis B immunization with a yeast-derived vaccine: Serological response by sex and age. Epidemiol Infect 1989; 103: 387-94.
8. Gonzales ML, Usandizaga M, Alomar P, Salva F, Martin F, Erroz M et al. Intradermal and intramuscular route for vaccination against hepatitis B. Vaccine 1990; 8: 402-5.
9. Rogan PD, Duguid KM. Immunisation of staff of a regional blood transfusion centre with a recombinant hepatitis B vaccine. J Infect 1991; 22: 5-9.
10. Nøkleby H, Lystad A. Hepatitt B vaksine: anbefalninger om antistoffmålning og revaksinasjon. MSIS-report 1994; 22: 1.
11. Bryan J, Sjogren M, Perine P, Legters L. Low-dose intradermal and intramuscular vaccination against hepatitis B. Clin Infect Dis 1992; 14: 697-707.
12. Aronsson B, Frenning B, Struve J, Weiland O. Förebyggande hepatit B-vaccination av sjukvårdspersonal lönsam investering. Läkartidningen 1990; 87: 2775-6.
13. Bergman J, Mares I, Eriksson G, Järnmark O, Ringkvist I. Vaccinationsmetod för effektivare intradermal immunisering mot hepatit B. Svenska läkaresällskapets handlingar Hygiea 1993; 102 (häfte 3): 176.
14. Odén I, Jörbeck H. Hepatit B-vaccination av sjukvårdspersonal. Dyrast ge vaccin intramuskulärt. Läkartidningen 1994; 91: 596-7.
15. Wiström J, Settergren B, Gustafsson Å, Juto P, Norrby RS. Intradermal vs intramuscular hepatitis B vaccinations. JAMA 1990; 264: 181-2.